This groundbreaking medication has the potential to significantly alter the trajectory of the AIDS epidemic. However, under the Trump administration, funding initiatives that could have supported its distribution in low-income nations have been severely reduced. As we approach 2025, the impact of these policy changes on global health could prove detrimental to efforts aimed at combating this persistent crisis.